Annual report pursuant to Section 13 and 15(d)

Discontinued Operations (Tables)

v3.21.1
Discontinued Operations (Tables)
 12 Months Ended
Dec. 31, 2020
Discontinued Operations  
Schedule of components of loss from discontinued operations as reported in our statements of operations and assets and liabilities reported as discontinued operations in our balance

 

 

 

 

 

 

 

 

    

Years ended December 31,

 

 

2020

 

2019

 

 

(In thousands, except per share data)

Revenue:

 

 

  

 

 

  

Product revenue

 

$

376

 

$

1,006

Costs and expenses:

 

 

  

 

 

  

Cost of goods sold

 

 

1,332

 

 

1,288

Research and development

 

 

1,917

 

 

2,162

Selling, general and administrative

 

 

7,224

 

 

6,524

Total costs and expenses

 

 

10,473

 

 

9,974

Loss from discontinued operations

 

 

(10,097)

 

 

(8,968)

Other expense, net

 

 

738

 

 

 —

Net loss from discontinued operations

 

$

10,835

 

$

(8,968)

Basic and diluted net loss per common share from discontinued operations

 

$

(2.87)

 

$

(11.71)

Weighted average shares used in computing basic and diluted net loss per common share

 

 

3,773

 

 

766

 


 

 

 

 

 

 

 

 

    

December 31,

 

 

2020

 

2019

 

 

(In thousands)

Receivables

 

$

 —

    

$

555

Inventory

 

 

 —

 

 

435

Prepaid expenses and other current assets

 

 

181

 

 

560

Discontinued operations – current assets

 

$

181

 

$

1,550

 

 

 

 

 

 

 

Accounts payable

 

$

1,515

 

$

585

Accrued clinical trials expenses

 

 

80

 

 

140

Accrued sales allowances

 

 

61

 

 

809

Other accrued liabilities

 

 

304

 

 

546

Discontinued operations – current liabilities

 

$

1,960

 

$

2,080